KR20070119714A - 리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법 - Google Patents

리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법 Download PDF

Info

Publication number
KR20070119714A
KR20070119714A KR1020077025071A KR20077025071A KR20070119714A KR 20070119714 A KR20070119714 A KR 20070119714A KR 1020077025071 A KR1020077025071 A KR 1020077025071A KR 20077025071 A KR20077025071 A KR 20077025071A KR 20070119714 A KR20070119714 A KR 20070119714A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
acceptable salt
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077025071A
Other languages
English (en)
Korean (ko)
Inventor
마틴 웨이드 비슬리
데이비드 피. 하우스
어윈 클라인
찰스 엘. 팜린
데이비드 존 레이놀즈
케빈 에이치. 실즈
Original Assignee
킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 filed Critical 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨
Publication of KR20070119714A publication Critical patent/KR20070119714A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077025071A 2005-03-31 2006-03-31 리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법 Withdrawn KR20070119714A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66662105P 2005-03-31 2005-03-31
US60/666,621 2005-03-31

Publications (1)

Publication Number Publication Date
KR20070119714A true KR20070119714A (ko) 2007-12-20

Family

ID=37054215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077025071A Withdrawn KR20070119714A (ko) 2005-03-31 2006-03-31 리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법

Country Status (11)

Country Link
US (1) US20060246133A1 (enExample)
EP (1) EP1863446A2 (enExample)
JP (1) JP2008534621A (enExample)
KR (1) KR20070119714A (enExample)
CN (1) CN101175477A (enExample)
AU (1) AU2006230557A1 (enExample)
BR (1) BRPI0609779A2 (enExample)
CA (1) CA2603313A1 (enExample)
IL (1) IL185723A0 (enExample)
MX (1) MX2007011826A (enExample)
WO (1) WO2006105482A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
ATE553753T1 (de) * 2007-02-16 2012-05-15 Suisse Electronique Microtech Überprüfungsverfahren
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
KR20180132955A (ko) * 2016-05-03 2018-12-12 스펙트릭스 테라퓨틱스, 엘엘씨 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
US10695309B2 (en) * 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
US11964048B2 (en) * 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine
EP4511009A1 (en) * 2022-04-22 2025-02-26 Prolevi Bio AB Compositions for modified release of active ingredients
CN115645361B (zh) * 2022-09-30 2023-11-21 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0550108B1 (en) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods

Also Published As

Publication number Publication date
US20060246133A1 (en) 2006-11-02
AU2006230557A1 (en) 2006-10-05
BRPI0609779A2 (pt) 2011-10-18
JP2008534621A (ja) 2008-08-28
CA2603313A1 (en) 2006-10-05
CN101175477A (zh) 2008-05-07
WO2006105482A2 (en) 2006-10-05
IL185723A0 (en) 2008-01-06
WO2006105482A3 (en) 2006-12-07
MX2007011826A (es) 2007-11-22
EP1863446A2 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
DK1351668T3 (en) Pharmaceutical dosage forms with delayed release and minimized with pH-dependent solubility profiles
JP5816091B2 (ja) ナトリウムオキシベートの即時放出投薬形態
US8318203B2 (en) Form of administration of racecadotril
MXPA05002827A (es) Formulaciones farmaceuticas de modafinil.
US20240165034A1 (en) Mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
AU2002249881A1 (en) Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles
JP5879359B2 (ja) クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用
BG65322B1 (bg) Орални състави за агонисти или антагонисти на 5-ht долу 4
KR20070119714A (ko) 리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법
US9662296B2 (en) Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiases and related diseases
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454B (en) Tablet for use in treating huntington's disease and method of making the same
HK40066088A (en) A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
BR112018068143B1 (pt) Forma farmacêutica unitária oral de mazindol na forma de comprimido do tipo multicamada, processo para preparar a forma farmacêutica unitária, uso de uma forma farmacêutica unitária de mazindol e uso de mazindol
JPWO2022067039A5 (enExample)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid